Spastic ataxia-corneal dystrophy syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:2572OMIM:271320G11.8
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Spastic ataxia-corneal dystrophy syndrome is an extremely rare genetic condition that affects both the nervous system and the eyes. The disease combines two main problems: spastic ataxia, which causes stiffness (spasticity) and poor coordination of movements (ataxia), and corneal dystrophy, which involves clouding or abnormal changes in the clear front surface of the eye (the cornea). People with this condition typically experience progressive difficulty with walking and balance due to the combination of muscle stiffness and uncoordinated movements. Over time, vision may also become impaired as the cornea becomes increasingly cloudy or irregular. Because this syndrome is so rare, it has been described in only a very small number of families in the medical literature. The neurological symptoms tend to worsen gradually over time, and the corneal changes can lead to significant visual problems. There is currently no cure for this condition. Treatment focuses on managing symptoms, including physical therapy to help with movement difficulties, medications to reduce muscle stiffness, and ophthalmological interventions such as corneal transplantation if vision loss becomes severe. A team of specialists working together is important for providing the best possible care.

Also known as:

Key symptoms:

Muscle stiffness in the legs (spasticity)Poor coordination and unsteady walking (ataxia)Clouding of the front surface of the eye (corneal dystrophy)Progressive difficulty with balanceVision problems or blurred visionDifficulty walkingIncreased muscle reflexesLeg weaknessSlurred or slow speechDifficulty with fine motor tasks like writing or buttoning clothes

Clinical phenotype terms (12)— hover any for plain English
Spastic ataxiaHP:0002497Spinocerebellar tract degenerationHP:0002503
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Spastic ataxia-corneal dystrophy syndrome.

View clinical trials →

No actively recruiting trials found for Spastic ataxia-corneal dystrophy syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Spastic ataxia-corneal dystrophy syndrome community →

No specialists are currently listed for Spastic ataxia-corneal dystrophy syndrome.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Spastic ataxia-corneal dystrophy syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Spastic ataxia-corneal dystrophy syndromeForum →

No community posts yet. Be the first to share your experience with Spastic ataxia-corneal dystrophy syndrome.

Start the conversation →

Latest news about Spastic ataxia-corneal dystrophy syndrome

No recent news articles for Spastic ataxia-corneal dystrophy syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.How quickly is this condition likely to progress in my case?,What genetic testing should I and my family members consider?,What physical therapy program would be most helpful for maintaining my mobility?,When should we consider corneal transplantation for my eye problems?,Are there any clinical trials or research studies I could participate in?,What medications can help with my muscle stiffness, and what are the side effects?,What resources are available to help me adapt my home and daily routine?

Common questions about Spastic ataxia-corneal dystrophy syndrome

What is Spastic ataxia-corneal dystrophy syndrome?

Spastic ataxia-corneal dystrophy syndrome is an extremely rare genetic condition that affects both the nervous system and the eyes. The disease combines two main problems: spastic ataxia, which causes stiffness (spasticity) and poor coordination of movements (ataxia), and corneal dystrophy, which involves clouding or abnormal changes in the clear front surface of the eye (the cornea). People with this condition typically experience progressive difficulty with walking and balance due to the combination of muscle stiffness and uncoordinated movements. Over time, vision may also become impaired a

How is Spastic ataxia-corneal dystrophy syndrome inherited?

Spastic ataxia-corneal dystrophy syndrome follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.